We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

2 hedge funds and large institutions have $10.1K invested in ELITE PHARMACEUTICAL in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 3 → 2 (-1)

89% less capital invested

Capital invested by funds: $94.3K → $10.1K (-$84.2K)

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q3 2017 in Review

2 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2017, worth a combined $10.1K — down 89% from $94.3K a quarter earlier.

Fund positioning in ELI was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q3 2017, down from 3 in Q2 2017.
  • Funds reported $10.1K of ELITE PHARMACEUTICAL stock for Q3 2017, down 89% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q3 2017 and 0 closed out.

Based on aggregated 13F filings for Q3 2017.